Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans

@article{Lipkowitz2013ApolipoproteinLG,
  title={Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans},
  author={Michael Lipkowitz and Barry I. Freedman and Carl D. Langefeld and Mary E. Comeau and Donald W. Bowden and Wen Kao and Brad C. Astor and Erwin P. Bottinger and Sudha K Iyengar and Paul E. Klotman and Richard Gabriel Freedman and Weijia Zhang and Rulan S. Parekh and Michael J. Choi and George W. Nelson and Cheryl A. Winkler and Jeffrey B. Kopp},
  journal={Kidney international},
  year={2013},
  volume={83},
  pages={114 - 120}
}
Despite intensive anti-hypertensive therapy there was a high incidence of renal end-points in participants of the African American Study of Kidney Disease and Hypertension (AASK) cohort. To better understand this, coding variants in the apolipoprotein L1 (APOL1) and the non-muscle myosin heavy chain 9 (MYH9) genes were evaluated for an association with hypertension-attributed nephropathy and clinical outcomes in a case-control study. Clinical data and DNA were available for 675 AASK participant… 
Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease
TLDR
The findings strongly suggest for the first time that two APOL1 risk alleles in young hypertensive African Americans with a family history of ESRD are strongly associated with kidney disease.
APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD.
TLDR
Among blacks with established moderate CKD, the APOL1 high-risk variants are associated with greater risk of incident proteinuria and after proteinuria onset, kidney function declines more rapidly but does not differ by APol1 risk status.
Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial.
TLDR
Combined effects of GSTM1 null and APOL1 high-risk alleles deleteriously affect CKD progression among blacks with hypertension, and subjects with both GSTM 1 null andAPOL1high-risk genotypes had highest risk of adverse renal outcomes.
APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension)
TLDR
Among African Americans with hypertension-attributed chronic kidney disease, APOL1 risk variants were not associated with an overall risk for cardiovascular disease although some signals for cardiovascular mortality were noted.
Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial
TLDR
Data from the Systolic Blood Pressure Intervention Trial (SPRINT) show that APOL1 risk variants are associated with mild CKD but not prevalent CVD in African American with a UACR under 1000 mg/g.
APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes
TLDR
Albuminuria and reduced eGFR associate with two apolipoprotein L1 gene (APOL1) variants in non-diabetic African Americans and are significantly associated with reduced risk of death in African Americans with type 2 diabetes mellitus.
Apolipoprotein L1 High-Risk Genotypes and Albuminuria in Sub-Saharan African Populations.
TLDR
APOL1 G1 and G2 alleles and high-risk genotype frequencies differed between and within West and South Africa and were almost absent from East Africa.
Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans.
High Population Frequencies of APOL1 Risk Variants Are Associated with Increased Prevalence of Non-Diabetic Chronic Kidney Disease in the Igbo People from South-Eastern Nigeria
TLDR
APOL1 risk variants are common in the Igbo population of south-eastern Nigeria, and are also highly associated with non-diabetic CKD in this area, suggesting that APOL1 may explain the increased prevalence of CKd in this region.
...
...

References

SHOWING 1-10 OF 28 REFERENCES
Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.
TLDR
The study shows that gene-environment and/or gene-gene interactions may initiate kidney disease in genetically susceptible individuals, because African Americans homozygous for MYH9 risk alleles do not universally develop kidney disease.
The MYH9/APOL1 region and chronic kidney disease in European-Americans.
TLDR
The data suggest that the MYH9 polymorphism rs4821480 is associated with an increased risk of non-diabetic CKD in individuals of European ancestry.
Progression of Chronic Kidney Disease: Adrenergic Genetic Influence on Glomerular Filtration Rate Decline in Hypertensive Nephrosclerosis
TLDR
The findings were extended to an independent case/control sample of Black hypertensive ESRD, in which it was found that variant Gly16Arg that tagged the GFR slope-determining ADRB2 haplotype also conferred risk for the E SRD trait in Blacks.
Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans.
  • Jessica N. Cooke, Meredith A. Bostrom, D. Bowden
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2012
TLDR
MyH9 SNPs rs4821480, rs2032487, rs4281481 and rs3752462 are associated with T2DM-ESRD susceptibility in European Americans and appear to influence nephropathy risk in this sample.
MYH9 is associated with nondiabetic end-stage renal disease in African Americans
TLDR
Multiple common SNPs in the gene encoding nonmuscle myosin heavy chain type II isoform A (MYH9) were associated with two to four times greater risk of nondiabetic E SRD and accounted for a large proportion of the excess risk of ESRD observed in African compared to European Americans.
MYH9 and APOL1 are both associated with sickle cell disease nephropathy
TLDR
The data provide insight into the pathobiology of renal dysfunction in SCD, suggesting that myosin, heavy chain 9, non‐muscle (MYH9) and apolipoprotein L1 (APOL1) are both associated with risk.
Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC).
  • M. Fung, R. Salem, D. O'Connor
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2012
TLDR
It is concluded that the MTHFR-coding polymorphism at A1298C is associated with renal decline in African-Americans with hypertensive nephrosclerosis and is supported by a veteran cohort with a primary care diagnosis of hypertension.
Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene
TLDR
This work uses recently released sequences from the 1000 Genomes Project to identify two western African-specific missense mutations in the neighboring APOL1 gene, and demonstrates that these are more strongly associated with ESKD than previously reported MYH9 variants.
Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators.
African Americans have excess hypertension and end-stage renal disease presumed due to hypertension compared to Caucasians. The AASK was designed to examine the impact of antihypertensive therapies
...
...